201 related articles for article (PubMed ID: 23606705)
1. The degree of skin involvement identifies distinct lung disease outcomes and survival in systemic sclerosis.
Cottrell TR; Wise RA; Wigley FM; Boin F
Ann Rheum Dis; 2014 Jun; 73(6):1060-6. PubMed ID: 23606705
[TBL] [Abstract][Full Text] [Related]
2. Lung involvement in systemic sclerosis (scleroderma): relation to classification based on extent of skin involvement or autoantibody status.
Kane GC; Varga J; Conant EF; Spirn PW; Jimenez S; Fish JE
Respir Med; 1996 Apr; 90(4):223-30. PubMed ID: 8736656
[TBL] [Abstract][Full Text] [Related]
3. Survival prognostic factors and markers of morbidity in Spanish patients with systemic sclerosis.
Simeon CP; Armadans L; Fonollosa V; Vilardell M; Candell J; Tolosa C; Mearin F; Rodrigo MJ; Solans R; Lima J; Sampol G
Ann Rheum Dis; 1997 Dec; 56(12):723-8. PubMed ID: 9496151
[TBL] [Abstract][Full Text] [Related]
4. Anti-PM-Scl antibody in patients with systemic sclerosis.
Koschik RW; Fertig N; Lucas MR; Domsic RT; Medsger TA
Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S12-6. PubMed ID: 22261302
[TBL] [Abstract][Full Text] [Related]
5. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis.
Hamaguchi Y
J Dermatol; 2010 Jan; 37(1):42-53. PubMed ID: 20175839
[TBL] [Abstract][Full Text] [Related]
6. Cardiopulmonary Disease Development in Anti-RNA Polymerase III-positive Systemic Sclerosis: Comparative Analyses from an Unselected, Prospective Patient Cohort.
Hoffmann-Vold AM; Midtvedt Ø; Tennøe AH; Garen T; Lund MB; Aaløkken TM; Andreassen AK; Elhage F; Brunborg C; Taraldsrud E; Molberg Ø
J Rheumatol; 2017 Apr; 44(4):459-465. PubMed ID: 28089974
[TBL] [Abstract][Full Text] [Related]
7. Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis.
Nihtyanova SI; Sari A; Harvey JC; Leslie A; Derrett-Smith EC; Fonseca C; Ong VH; Denton CP
Arthritis Rheumatol; 2020 Mar; 72(3):465-476. PubMed ID: 31682743
[TBL] [Abstract][Full Text] [Related]
8. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis.
Jacobsen S; Ullman S; Shen GQ; Wiik A; Halberg P
J Rheumatol; 2001 Nov; 28(11):2454-9. PubMed ID: 11708418
[TBL] [Abstract][Full Text] [Related]
9. Survival in systemic sclerosis-pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry.
Hinchcliff M; Khanna S; Hsu VM; Lee J; Almagor O; Chang RW; Steen V; Chung L;
Semin Arthritis Rheum; 2015 Dec; 45(3):309-14. PubMed ID: 26210782
[TBL] [Abstract][Full Text] [Related]
10. The Belgian Systemic Sclerosis Cohort: correlations between disease severity scores, cutaneous subsets, and autoantibody profile.
Vanthuyne M; Smith V; De Langhe E; Van Praet J; Arat S; Depresseux G; Westhovens R; Blockmans D; Badot V; Cogan E; De Keyser F; Houssiau FA
J Rheumatol; 2012 Nov; 39(11):2127-33. PubMed ID: 22984273
[TBL] [Abstract][Full Text] [Related]
11. Thinking outside the box--The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect.
Srivastava N; Hudson M; Tatibouet S; Wang M; Baron M; Fritzler MJ;
Semin Arthritis Rheum; 2015 Oct; 45(2):184-9. PubMed ID: 25959492
[TBL] [Abstract][Full Text] [Related]
12. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis.
Meyer OC; Fertig N; Lucas M; Somogyi N; Medsger TA
J Rheumatol; 2007 Jan; 34(1):104-9. PubMed ID: 17117486
[TBL] [Abstract][Full Text] [Related]
13. Good outcome of interstitial lung disease in patients with scleroderma associated to anti-PM/Scl antibody.
Guillen-Del Castillo A; Pilar Simeón-Aznar C; Fonollosa-Pla V; Alonso-Vila S; Reverte-Vinaixa MM; Muñoz X; Pallisa E; Selva-O'allaghan A; Fernández-Codina A; Vilardell-Tarrés M
Semin Arthritis Rheum; 2014 Dec; 44(3):331-7. PubMed ID: 25110305
[TBL] [Abstract][Full Text] [Related]
14. Autoantibody profile in systemic sclerosis as a marker for esophageal and other organ involvement in Turkish populations.
Savas N; Dagli U; Ertugrul E; Kuran S; Sahin B
Dig Dis Sci; 2007 Nov; 52(11):3081-6. PubMed ID: 17393310
[TBL] [Abstract][Full Text] [Related]
15. Characteristics and Survival of Anti-U1 RNP Antibody-Positive Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.
Sobanski V; Giovannelli J; Lynch BM; Schreiber BE; Nihtyanova SI; Harvey J; Handler CE; Denton CP; Coghlan JG
Arthritis Rheumatol; 2016 Feb; 68(2):484-93. PubMed ID: 26415038
[TBL] [Abstract][Full Text] [Related]
16. Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database.
Wirz EG; Jaeger VK; Allanore Y; Riemekasten G; Hachulla E; Distler O; Airò P; Carreira PE; Tikly M; Vettori S; Balbir Gurman A; Damjanov N; Müller-Ladner U; Distler J; Li M; Häusermann P; Walker UA;
Ann Rheum Dis; 2016 Jul; 75(7):1285-92. PubMed ID: 26232495
[TBL] [Abstract][Full Text] [Related]
17. Significance of anti-neutrophil cytoplasmic antibodies in systemic sclerosis.
Moxey J; Huq M; Proudman S; Sahhar J; Ngian GS; Walker J; Strickland G; Wilson M; Ross L; Major G; Roddy J; Stevens W; Nikpour M
Arthritis Res Ther; 2019 Feb; 21(1):57. PubMed ID: 30764870
[TBL] [Abstract][Full Text] [Related]
18. Serological and clinical profile of systemic sclerosis: analysis in a cohort of patients from a single center in Northern Italy.
Priora M; Manetta T; Scarati M; Parisi S; Laganà A; Peroni CL; Bruzzone M; Borrelli R; Rende M; Mengozzi G; Fusaro E
G Ital Dermatol Venereol; 2018 Feb; 153(1):33-38. PubMed ID: 27055150
[TBL] [Abstract][Full Text] [Related]
19. RNA polymerase III autoantibodies may indicate renal and more severe skin involvement in systemic sclerosis.
Terras S; Hartenstein H; Höxtermann S; Gambichler T; Kreuter A
Int J Dermatol; 2016 Aug; 55(8):882-5. PubMed ID: 26499848
[TBL] [Abstract][Full Text] [Related]
20. Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysis.
Sharif R; Fritzler MJ; Mayes MD; Gonzalez EB; McNearney TA; Draeger H; Baron M; ; Furst DE; Khanna DK; del Junco DJ; Molitor JA; Schiopu E; Phillips K; Seibold JR; Silver RM; Simms RW; ; Perry M; Rojo C; Charles J; Zhou X; Agarwal SK; Reveille JD; Assassi S; Arnett FC
J Rheumatol; 2011 Aug; 38(8):1622-30. PubMed ID: 21572159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
